Psychostimulant and opioid abuse: A perspective from Uruguay.

Neuroscience

Departamento de Neurofarmacología Experimental, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay. Electronic address:

Published: March 2025

The number of people suffering from Substance Use Disorder (SUD) worldwide has increased 45 % compared to the last decade according to the latest United Nations World Drug Report. This staggering increase, partly due to the recent COVID-19 pandemic, further raises the social and economic burden for nations. Prevention and treatment, two of the main strategies employed to curb the increase in SUD, have shown limited success despite our increasing understanding of the underlying processes of SUD. This review will focus on two main drug categories, psychostimulants, especially cocaine, and opioids since these are two of the most prevalent illicit drugs abused by the general public in low, middle, and high-income countries. The use of active adulterants (e.g., caffeine and illegally manufactured fentanyl-IMF) commonly employed in the preparation of illicit drugs will also be covered considering recent data which has shown that these adulterants may increase the health risk of psychostimulant and opioid users. Especially the high risk of the combined use of cocaine and IMF is detailed. An additional section will address drug abuse in women during pregnancy, as it constitutes a major public health concern due to the negative consequences on newborns and infants. The Uruguayan scenario is presented to provide at least a general overview of the topic of interest. The rapidly changing drug market, together with the current prevalence of SUD, establishes the urgent need for new strategies and innovative treatments to manage this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroscience.2025.03.014DOI Listing

Publication Analysis

Top Keywords

psychostimulant opioid
8
illicit drugs
8
opioid abuse
4
abuse perspective
4
perspective uruguay
4
uruguay number
4
number people
4
people suffering
4
suffering substance
4
substance disorder
4

Similar Publications

Psychostimulant and opioid abuse: A perspective from Uruguay.

Neuroscience

March 2025

Departamento de Neurofarmacología Experimental, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay. Electronic address:

The number of people suffering from Substance Use Disorder (SUD) worldwide has increased 45 % compared to the last decade according to the latest United Nations World Drug Report. This staggering increase, partly due to the recent COVID-19 pandemic, further raises the social and economic burden for nations. Prevention and treatment, two of the main strategies employed to curb the increase in SUD, have shown limited success despite our increasing understanding of the underlying processes of SUD.

View Article and Find Full Text PDF

The recreational abuse of addictive drugs poses considerable challenges to public health, leading to widespread neurotoxicity and neurological dysfunction. This review comprehensively examines the neurotoxic mechanisms, clinical manifestations, and treatment strategies associated with six commonly abused substances: methamphetamine, cocaine, synthetic cathinones, ketamine, nitrous oxide and heroin. Despite their diverse pharmacological properties, these drugs converge on shared neurotoxic pathways, including oxidative stress, mitochondrial dysfunction, excitotoxicity, and neuroinflammation.

View Article and Find Full Text PDF

Rationale: Opioid misuse is a prominent public health concern, although patterns of use may confer different vulnerability to relapse. Continuous-access (ContA) self-administration has traditionally been used in preclinical models to study drug-motivated behaviors and produces robust escalation of intake and tolerance development. Alternatively, studies using intermittent access (IntA), where self-administration occurs in discrete drug-available periods, suggest that overall intake may be dissociable from subsequent increases in motivation (i.

View Article and Find Full Text PDF

Prescribing Psychostimulants for the Treatment of Stimulant Use Disorder: Navigating the Federal Legal Landscape.

J Addict Med

February 2025

Division of General Internal Medicine, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, CA (LWS); San Francisco Department of Public Health, San Francisco, CA (POC); Vital Strategies, New York, NY (KB, DC); Network for Public Health Law, Edina, MN (CSD); and New York University Grossman School of Medicine, New York, NY (CSD).

Stimulant use disorder (StUD) is a rapidly growing concern in the United States, with escalating rates of death attributed to amphetamines and cocaine. No medications are currently approved for StUD treatment, leaving clinicians to navigate off-label medication options. Recent studies suggest that controlled prescription psychostimulants such as dextroamphetamine, methylphenidate, and modafinil are associated with reductions in self-reported stimulant use, craving, and depressive symptoms.

View Article and Find Full Text PDF

Background: In 2020, Maryland had the fourth-highest opioid overdose mortality rate in the USA. We describe substances identified in postmortem toxicology screening and designated as cause of death (COD) for overdose decedents in Maryland, including specific combinations of substances designated as COD.

Methods: We performed a retrospective analysis of N=5442 adult overdose decedents (ie, manner of death unintentional or undetermined) in Maryland between January 2020 and December 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!